Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Radiation dose and late failures in prostate cancer.

Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1074-81. Epub 2006 Dec 29.

2.

Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy.

Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A.

Cancer. 2007 Jul 1;110(1):68-80.

3.

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11.

PMID:
11849793
4.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
5.

The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.

Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM.

Cancer. 2008 Jan 1;112(1):55-60.

6.

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.

Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1455-62. Epub 2005 Sep 19.

PMID:
16169682
7.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.

PMID:
14575823
8.

Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):993-1002.

PMID:
15752878
9.

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.

Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL.

J Urol. 2005 Mar;173(3):797-802.

PMID:
15711272
10.

Identifying differences between biochemical failure and cure: incidence rates and predictors.

Vicini FA, Shah C, Kestin L, Ghilezan M, Krauss D, Ye H, Brabbins D, Martinez AA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e369-75. doi: 10.1016/j.ijrobp.2011.05.017. Epub 2011 Jul 19.

PMID:
21764524
11.
12.

Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):14-9.

PMID:
15629589
13.

The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer.

Vicini FA, Kestin LL, Martinez AA.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):553-61.

PMID:
10524405
15.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
16.

Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.

Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):19-23.

PMID:
12909210
17.

Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):721-8. doi: 10.1016/j.ijrobp.2013.03.028. Epub 2013 May 9.

PMID:
23664325
18.

High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.

J Urol. 2001 Sep;166(3):876-81. Erratum in: J Urol 2001 Nov;166(5):1839.

PMID:
11490237
19.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
Items per page

Supplemental Content

Write to the Help Desk